Histopathological Features of HER2 Overexpression in Uterine Carcinosarcoma: Proposal for Requirements in HER2 Testing for Targeted Therapy

Overview

Journal Virchows Arch

Specialties Cell Biology
Molecular Biology
Pathology

Date 2021 Jan 10

PMID 33423127

Citations 7

Authors

Hiroshi Yoshida

Tadaaki Nishikawa

Koji Matsumoto

Masahiko Mori

Yasuyuki Hirashima

Kazuhiro Takehara

Kazuya Ariyoshi

Kosei Hasegawa

Kan Yonemori

Affiliations

Soon will be listed here.

Abstract

Uterine carcinosarcoma (UCS) is an uncommon and highly aggressive tumor. There is no HER2 testing protocol for UCS despite the development of HER2 antibody conjugates. We aimed to elucidate histopathological HER2 expression details in UCS, to compare HER2 scores between ASCO/CAP criteria for gastric and breast cancer, and to propose requirements for HER2 testing for UCS. Eighty-nine specimens from 84 patients with metastatic/recurrent UCS were prospectively collected from May 2018 to July 2020. We performed HER2 immunohistochemistry (IHC) for 89 specimens and FISH for 44 specimens. HER2 expression details and HER2 score were evaluated according to the latest ASCO/CAP criteria for gastric (2016) and breast cancer (2018). HER2 IHC scores according to the gastric cancer criteria were 0 in 31 cases (35%), 1+ in 26 (29%), 2+ in 22 (25%), and 3+ in 10 cases (11%) of the 89 specimens. A lateral/basolateral membranous staining pattern was observed in 28/32 (88%) specimens with HER2 scores of 2+/3+. HER2 intratumoral heterogeneity was identified in 28/32 (88%) of the specimens with HER2 scores of 2+/3+. The overall concordance rate of HER2 score was 70% between the gastric and breast criteria. FISH revealed HER2 gene amplification in 10/44 (23%) specimens containing only lateral/basolateral membranous staining pattern. Based on the histopathological features of HER2 expression in UCS, a scoring system that accepts lateral/basolateral staining patterns should be applied. Furthermore, we proposed specific requirements for UCS testing, including specimen selection, scoring system, and calculating the proportion of HER2-positive cells.

Citing Articles

Clinicopathological and molecular features of tubo-ovarian carcinosarcomas: a series of 51 cases.

Liang F, Shi Y, Chen Y, Tao X, Ding J Front Oncol. 2024; 14:1427154.

PMID: 39239274 PMC: 11375614. DOI: 10.3389/fonc.2024.1427154.

HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma.

Mizoguchi C, Nishikawa T, Yoshida H, Yasuda M, Kato T, Hasegawa K J Gynecol Oncol. 2024; 36(1):e14.

PMID: 38991945 PMC: 11790987. DOI: 10.3802/jgo.2025.36.e14.

Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression.

Kitadai R, Nishikawa T, Yoshida H, Mizoguchi C, Yamamoto K, Kato T J Gynecol Oncol. 2023; 35(2):e11.

PMID: 37914528 PMC: 10948979. DOI: 10.3802/jgo.2024.35.e11.

Alteration in molecular properties during establishment and passaging of endometrial carcinoma patient-derived xenografts.

Imai T, Yoshida H, Machida Y, Kuramochi M, Ichikawa H, Kubo T Sci Rep. 2023; 13(1):8511.

PMID: 37231035 PMC: 10212914. DOI: 10.1038/s41598-023-35703-6.

Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.

Nishikawa T, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K J Clin Oncol. 2023; 41(15):2789-2799.

PMID: 36977309 PMC: 10414746. DOI: 10.1200/JCO.22.02558.

References

Pradhan T, Stevens E, Ablavsky M, Salame G, Lee Y, Abulafia O . FIGO staging for carcinosarcoma: can the revised staging system predict overall survival?. Gynecol Oncol. 2011; 123(2):221-4. DOI: 10.1016/j.ygyno.2011.08.007. View

Fujii H, Yoshida M, Gong Z, Matsumoto T, Hamano Y, Fukunaga M . Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res. 2000; 60(1):114-20. View

Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English D . Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc Natl Acad Sci U S A. 2016; 113(43):12238-12243. PMC: 5087050. DOI: 10.1073/pnas.1614120113. View

Yamada S, Burger R, Brewster W, Anton D, Kohler M, Monk B . Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 2000; 88(12):2782-6. DOI: 10.1002/1097-0142(20000615)88:12<2782::aid-cncr17>3.0.co;2-k. View

Ferguson S, Tornos C, Hummer A, Barakat R, Soslow R . Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol. 2007; 31(11):1653-61. DOI: 10.1097/PAS.0b013e3181161ba3. View

Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, Verbist L, Moerman P . ERBB-2 gene overexpression and amplification in uterine sarcomas. Gynecol Oncol. 2004; 95(3):583-7. DOI: 10.1016/j.ygyno.2004.07.041. View

Livasy C, Catrina Reading F, Moore D, Boggess J, Lininger R . EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol. 2005; 100(1):101-6. DOI: 10.1016/j.ygyno.2005.07.124. View

Swisher E, Gown A, Skelly M, Ek M, Tamimi H, Cain J . The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Gynecol Oncol. 1996; 60(1):81-8. DOI: 10.1006/gyno.1996.0015. View

Saglam O, Husain S, Toruner G . AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma. Int J Gynecol Pathol. 2013; 32(5):493-500. DOI: 10.1097/PGP.0b013e31827fedef. View

10.

Rottmann D, Snir O, Wu X, Wong S, Hui P, Santin A . HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. Mod Pathol. 2019; 33(1):118-127. DOI: 10.1038/s41379-019-0358-x. View

11.

Fader A, Roque D, Siegel E, Buza N, Hui P, Abdelghany O . Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. J Clin Oncol. 2018; 36(20):2044-2051. DOI: 10.1200/JCO.2017.76.5966. View

12.

Santin A, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J . Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002; 8(5):1271-9. View

13.

Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop I, Redfern C . Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019; 20(6):816-826. DOI: 10.1016/S1470-2045(19)30097-X. View

14.

Shitara K, Bang Y, Iwasa S, Sugimoto N, Ryu M, Sakai D . Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020; 382(25):2419-2430. DOI: 10.1056/NEJMoa2004413. View

15.

Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N . DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016; 22(20):5097-5108. DOI: 10.1158/1078-0432.CCR-15-2822. View

16.

Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T . Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016; 107(7):1039-46. PMC: 4946713. DOI: 10.1111/cas.12966. View

17.

Modi S, Park H, Murthy R, Iwata H, Tamura K, Tsurutani J . Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol. 2020; 38(17):1887-1896. PMC: 7280051. DOI: 10.1200/JCO.19.02318. View

18.

Bartley A, Washington M, Colasacco C, Ventura C, Ismaila N, Benson 3rd A . HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017; 35(4):446-464. DOI: 10.1200/JCO.2016.69.4836. View

19.

Wolff A, Hammond M, Allison K, Harvey B, Mangu P, Bartlett J . Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018; 36(20):2105-2122. DOI: 10.1200/JCO.2018.77.8738. View

20.

Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura R, Penault-Llorca F . HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012; 25(5):637-50. DOI: 10.1038/modpathol.2011.198. View